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Before the introduction of Haemophilus inﬂ  uenzae type 
b (Hib) conjugate vaccines, rates of invasive H. inﬂ  uenzae 
disease among indigenous people of the North American 
Arctic were among the highest in the world. Routine vaccina-
tion reduced rates to low levels; however, serotype replace-
ment with non–type b strains may result in a reemergence of 
invasive disease in children. We reviewed population-based 
data on invasive H. inﬂ  uenzae in Alaska and northern Can-
ada from 2000–2005; 138 cases were reported. Among 88 
typeable isolates, 42 (48%) were H. inﬂ  uenzae type a (Hia); 
35 (83%) occurred in indigenous peoples. Among Hia pa-
tients, median age was 1.1 years; 62% were male; 1 adult 
died. Common clinical manifestations included meningitis, 
pneumonia, and septic arthritis. Overall annual incidence 
was 0.9 cases per 100,000 population. Incidence among 
indigenous children <2 years of age in Alaska and northern 
Canada was 21 and 102, respectively. Serotype a is now the 
most common H. inﬂ  uenzae serotype in the North American 
Arctic; the highest rates are among indigenous children.
H
aemophilus inﬂ  uenzae causes illnesses ranging from 
local respiratory infection to serious invasive disease, 
including meningitis, epiglottitis, septic arthritis, and sep-
ticemia (1). Among the encapsulated strains (a to f) that 
have been identiﬁ  ed, H. inﬂ  uenzae serotype b (Hib) is the 
most virulent (1–4). Nonencapsulated (nontypeable) strains 
are usually associated with noninvasive infections but can 
cause invasive disease, including neonatal sepsis (2–5). 
Historically, Hib was the leading cause of bacterial menin-
gitis in the United States and Canada (6). However, since 
the introduction of Hib capsular polysaccharide-protein 
conjugate vaccine in 1988, the incidence of invasive Hib 
disease has declined dramatically. Data from the Centers 
for Disease Control and Prevention (CDC) show invasive 
Hib disease in the United States has decreased by 99% to 
<1 case per 100,000 children <5 years of age (7). Similar 
declines have been documented in Canada (8).
Indigenous people, deﬁ   ned as the original people 
of Alaska (Alaska Native people) and northern Canada 
(aboriginal people), are at increased risk for Hib disease 
(8–12) than the general populations of the United States 
and Canada, and the risk for disease peaks at an earlier age 
(12–14). While Hib vaccination led to the rapid decline of 
Hib disease in all populations including indigenous groups, 
indigenous children continue to have higher rates of Hib 
disease than nonindigenous children (12,15).
With widespread vaccination against Hib, concern 
has been raised about the potential for replacement disease 
caused by non–type b encapsulated strains. Protection con-
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ferred by the Hib vaccine is speciﬁ  c to the type b poly-
saccharide capsule. It was suggested that reducing carriage 
of the vaccine type may open an ecologic niche, allowing 
increased colonization with non–type b strains of H. inﬂ  u-
enzae with the potential to become invasive (6,16).
Non–type b H. inﬂ  uenzae disease is uncommon in chil-
dren; however, since the introduction of Hib vaccine, the 
relative importance of infections due to nonencapsulated 
and non–type b encapsulated H. inﬂ  uenzae has increased 
(3). Infections caused by nonencapsulated strains are more 
common in adults and are more likely to be associated with 
pneumonia, whereas infections caused by encapsulated 
strains tend to occur in younger children with a predomi-
nance of meningitis and bacteremia (3,17). Non–type b H. 
inﬂ  uenzae appears to be more common in persons with 
underlying medical illnesses, such as immunosuppressive 
conditions (3,4,17). The extent to which non-b H. inﬂ  uen-
zae causes invasive disease is not fully known (17). In some 
countries, only Hib disease is reportable; therefore, infor-
mation on other serotypes is lacking. However, numerous 
case reports of invasive H. inﬂ  uenzae disease caused by 
encapsulated non-b serotypes, particularly types a, e, and f, 
have been published (6,10,11,18–20).
Although uncommon, H. inﬂ  uenzae serotype a (Hia) 
has been reported to cause invasive disease, meningitis, 
pneumonia, and sepsis (3,20). Hia disease may occur more 
frequently in indigenous populations (10,11,21). Reports of 
invasive H. inﬂ  uenzae disease have identiﬁ  ed Hia in 7.8% 
of Australian aboriginal children and 16.7% of Apache 
children with invasive disease (10,21–23). The Navajo and 
White Mountain Apache populations have a higher rate 
of Hia disease than the general US population, and Hia is 
now a leading cause of invasive H. inﬂ  uenzae disease in 
these populations (10). Although high rates were discov-
ered during the period of surveillance (1988–2003), signiﬁ  -
cant increases in incidence were not found (10). Seasonal, 
temporal, and geographic clustering was not demonstrated. 
An outbreak of invasive Hia has recently been described 
in Alaska (11), and data from the International Circumpo-
lar Surveillance (ICS) Program suggest that the number 
of cases of Hia has increased in both Alaska and northern 
Canada. The objectives of this study were to characterize 
cases of invasive Hia, to examine incidence rates over time, 
and to assess the relatedness of Hia isolates by molecular 
typing.
Methods
ICS, a population-based surveillance system for inva-
sive bacterial diseases established in 1999, includes labo-
ratory-based surveillance for Streptococcus pneumoniae, 
H. inﬂ  uenzae, Neisseria meningitidis, and groups A and 
B streptococci. Current member countries include the US 
Arctic (Alaska), northern Canada, Greenland, Iceland, 
Norway, northern Sweden, and Finland.
This study reviews data collected from 2000 through 
2005 from Alaska and northern Canada. In Alaska, 23 labo-
ratories throughout the state are asked to send any isolate 
of H. inﬂ  uenzae recovered from a normally sterile site to a 
reference laboratory in Anchorage at CDC’s Arctic Inves-
tigations Program, which serves as the data repository for 
ICS. In northern Canada, a network of laboratories within 
the regions (Yukon, Northwest Territories, Nunavut, north-
ern Quebec, and northern Labrador) participate, as well as 
3 reference laboratories (2 national and 1 provincial). The 
laboratories are requested to send any isolate of H. inﬂ  uen-
zae recovered from a normally sterile site to the appropri-
ate reference laboratory to conﬁ  rm the identity, determine 
the serotype, and test for antimicrobial drug susceptibility. 
Laboratory, demographic, and clinical data are collected 
for each invasive case of H. inﬂ  uenzae occurring in Alaska 
and northern Canada, and these data are forwarded to ICS 
headquarters in Alaska.
A case of invasive H. inﬂ  uenzae disease is deﬁ  ned as 
illness in a resident of the surveillance area from whom H. 
inﬂ  uenzae is isolated from a sample obtained from a nor-
mally sterile site, including blood, cerebrospinal ﬂ  uid, pleu-
ral ﬂ  uid, peritoneal ﬂ  uid, or joint ﬂ  uid. Patients with clini-
cal epiglottitis from which H. inﬂ  uenzae is isolated from 
an epiglottis swab are also reportable to ICS. The primary 
clinical manifestation of H. inﬂ  uenzae was determined by a 
review of the patient’s medical record.
Population denominator data for Alaska and northern 
Canada were obtained from the Alaska Department of La-
bor and Workforce Development (www.labor.state.ak.us), 
Statistics Canada (www.statcan.ca), and the Demography 
Division of Statistics Canada. Estimates from Alaska and 
northern Canada reﬂ  ect population ﬁ  gures from the 2000 
and 2001 census years, respectively. Canadian indigenous 
estimates were calculated by using population data from 
the Aboriginal Population Proﬁ  le, which is developed from 
2001 Census data. This study covers a 6-year surveillance 
period, January 1, 2000–December 31, 2005. Alaska and 
northern Canada’s estimated populations were 655,435 and 
132,956, respectively. Indigenous peoples comprised 19% 
of the population in Alaska and 59% of the population in 
northern Canada.
Laboratory Methods
Isolates were streaked onto chocolate agar to check 
for purity and conﬁ  rmed to be H. inﬂ  uenzae. Conﬁ  rma-
tion tests included a requirement for both X (hemin) and 
V (nicotinamide adenine dinucleotide) growth factors (Ox-
oid, Hampshire, UK), Gram stain, and serotyping by slide 
agglutination.
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Antimicrobial Susceptibility Testing
Susceptibility testing in Alaska was performed by us-
ing Etest (AB Biodisk, Solna, Sweden). A direct colony 
suspension equivalent to a 0.5 MacFarland standard was 
prepared in Mueller-Hinton broth from an overnight cul-
ture. Haemophilus Test Medium (Remel, Lexna, KS, USA) 
was added to produce a conﬂ  uent lawn of growth, and then 
Etest strips were placed onto the plate. The plates were then 
incubated for 20–24 hours at 35°C in 5% CO2. The MIC was 
read at the point of intersection of growth and the strip. Sus-
ceptibility of H. inﬂ  uenzae to the following antimicrobial 
drugs was tested: ampicillin, ceftriaxone, meropenem, chlor-
amphenicol, and trimethoprim-sulfamethoxazole (TMP-
sulfa). Susceptibility data were not available from Canada.
Serotyping
Capsular serotyping was performed by slide agglu-
tination with Difco antisera (Difco, Detroit, MI, USA) in 
Alaska and Remel antisera (Remel Europe Ltd, Dartford, 
UK) in northern Canadian laboratories (with the exception 
of the Laboratoire de Sante Publique in Quebec, which 
used PCR). If no capsular polysaccharide was present, the 
isolate was classiﬁ  ed as nontypeable by slide agglutination. 
Known positive and negative controls were run weekly, and 
each culture was screened in saline alone to check for auto-
agglutination. Since 2005, laboratories have participated in 
an ongoing H. inﬂ  uenzae quality control program.
Pulsed-ﬁ  eld Gel Electrophoresis (PFGE) and PCR
A selection of invasive isolates of Hia from cases in 
Alaska and northern Canada that tested positive for sero-
type a by both slide agglutination and genotype-speciﬁ  c 
PCR (24) were examined by PFGE with the use of the 
restriction enzymes SmaI and ApaI digestions (18,25) at 
the CDC laboratory in Anchorage, Alaska. The fragments 
were resolved with a CHEF DRII (Bio-Rad, Hercules, CA, 
USA) (2.2- to 35-s switch times) at 175V for 21 hours. 
DNA banding patterns were analyzed with BioNumerics 
version 3.0 software (Applied Maths, Sint-Martens-Latem, 
Belgium). Percentage similarities were identiﬁ  ed on a den-
drogram derived from the unweighted pair group method 
by using Dice coefﬁ  cients and a band position tolerance of 
1.5%. A similarity coefﬁ  cient of 80% (<3-band difference) 
was used to deﬁ  ne related groups. The IS1016-bexA dele-
tion was ampliﬁ  ed from genomic DNA by PCR using sense 




Data were double entered into Paradox v9.0 (Corel, 
Ottawa, Ontario, Canada), and analyzed by using Epi Info 
version 6.04b (CDC, Atlanta, GA, USA) and StatXact ver-
sion 6.2 (CYTEL Software Corp., Cambridge, MA, USA). 
Statistical differences in rates between periods and between 
countries were assessed by using a 2-sample Poisson test; p 
values are exact when appropriate.
Results
Descriptive Epidemiology
We identiﬁ  ed 138 cases of invasive H. inﬂ  uenzae dis-
ease from 2000 through 2005; serotype data were available 
for 132 (96%) of the isolates. Among these, 44 (33%) were 
nontypeable (Alaska 27; northern Canada 17). Of the re-
maining 88 isolates, 42 (48%) were serotype a, 27 (31%) 
serotype b, 12 (14%) serotype f, 4 (5%) serotype d, 2 (2%) 
serotype c, and 1 (1%) serotype e (Figure 1). The propor-
tion of illnesses that resulted in death among Hia, encapsu-
lated non-a, and nontypeable isolates was 5% (2/37), 14% 
(6/42), and 15% (6/40), respectively.
Among the 42 Hia isolates, 30 (71%) occurred in chil-
dren <2 years of age; 4 (10%) occurred in children 2–5 years 
of age; the remaining 8 (19%) occurred in adults (range 
21–73 years). Ethnicity data were available for 38 cases; 
35 (92%) occurred in indigenous people. The median age 
among case-patients was 1.1 years (range 3 months to 73 
years) and did not differ signiﬁ  cantly by country. Overall, 
62% were male (Table 1). Cases occurred in 3 Alaska re-
gions and 3 regions in northern Canada. Most cases (60%) 
occurred in 1 northern Canadian region. No clear seasonal 
pattern of invasive Hia disease was observed; however, 5 
(50%) cases of invasive Hia that occurred in indigenous 
Alaska children <2 years of age were clustered over a 5-
month period in 2003 and occurred in 2 villages in western 
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Figure 1. Haemophilus inﬂ  uenzae (Hi) cases by serotype in Alaska 
and Northern Canada, 2000–2005. A) Alaska; n = 42 typeable (27 
nontypeable); 59% encapsulated non-b, 24% Hia. B) Northern 
Canada; n = 46 typeable (17 nontypeable); 81% encapsulated non-
b, 74% Hia.Haemophilus inﬂ  uenzae Serotype a, North American Arctic
Alaska (11). No clusters >2 cases in 1 village over a period 
of 2 months were observed in northern Canada. No pat-
tern of increasing incidence rates was seen over the study 
period.
Incidence Rates by Age
Overall crude annualized incidence of invasive Hia for 
the 6-year study period was 0.9 cases per 100,000 popu-
lation. In Alaska and northern Canada, crude annualized 
incidence rates were 0.3 and 3.9 cases per 100,000 popula-
tion, respectively. Annualized incidence rates of invasive 
Hia in children <2 years of age were 19.7 cases per 100,000 
population; annualized rates in Alaskan and northern Cana-
dian children <2 years were 5.7 and 79.1 cases per 100,000 
population, respectively (p<0.001, Table 2).
Incidence Rates by Ethnicity
The overall annualized crude incidence rates of inva-
sive Hia over the study period in indigenous and nonindig-
enous people were 2.9 and 0.2 cases per 100,000 popula-
tion, respectively. Among indigenous people, the overall 
annual crude incidence rates ranged from 2.0 to 4.0 cases 
per 100,000 population during the study period; annualized 
indigenous incidence rates in Alaska and northern Canada 
were 1.1 and 5.9 cases per 100,000 population, respectively 
(Table 2). Among indigenous children <2 years of age, the 
overall annualized incidence rate was 52.6 cases per 100,000 
population, 20.9 and 101.9 cases per 100,000 persons in 
Alaska and northern Canada, respectively (Table 2).
Clinical Illness
Among all ages, the most common clinical syndromes 
were meningitis (33%) and pneumonia (29%), followed 
by septic arthritis (12%). Clinical manifestations differed 
between children and adults. As noted previously, all pe-
diatric cases occurred in children <5 years of age. Adult 
case-patients were 21–73 years of age. Children were more 
likely to exhibit meningitis, and adults were more likely to 
exhibit pneumonia; septic arthritis was reported among 5 
(15%) pediatric patients. Clinical features were similar in 
Alaska and northern Canada. No cases of epiglottitis were 
reported (Table 3).
Of the 37 case-patients with known hospitalization sta-
tus, 35 (95%) were hospitalized with a median duration of 
8 days. Case-patients in Alaska had a shorter median dura-
tion of hospitalization than those in northern Canada (6.5 
vs. 9.0 days). Outcome information was available for 37 
cases. Two patients (1 indigenous child, 1 nonindigenous 
adult) with invasive Hia died (Table 1). Both patients who 
died were diagnosed with pneumonia; neither had a history 
of immunodeﬁ  ciency noted in the chart.
Recurrence
Two Alaskan Hia patients had recurrent disease. In 1 
patient, the clinical manifestation was septic arthritis in both 
occurrences (4 months before recurrence). In the second pa-
tient, the initial clinical syndrome was pneumonia, followed 
by meningitis 4 months later. Both of these patients were <1 
year of age when ﬁ  rst brought for treatment. Neither child 
had documented immunodeﬁ  ciency (11). No recurring cas-
es of Hia were documented in northern Canada.
Antimicrobial Susceptibility Testing
All 11 Hia isolates from Alaska were susceptible to 
ampicillin, ceftriaxone, meropenem, and chloramphenicol. 
Ten of 11 Hia isolates from Alaska were tested for TMP-
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Table 1. Characteristics of Alaskan and northern Canadian persons with invasive Haemophilus influenzae type a disease, 2000–2005 
Characteristic Alaska (n = 11)  Northern Canada (n = 31)  Total (n = 42) 
Median age (range)  10 mo (4 mo–73 y)  1.2 y (3 mo–31 y)  1.1 y (3 mo–73 y) 
Male sex, no. (%)  7 (64)  19 (61)  26 (62) 
Indigenous, no. (%)  8 (73)  27 (100)*  35 (92) 
Age appropriately vaccinated for 
Hib, y (% vaccinated) 
7 (88)†  21 (88)‡  28 (88) 
Hospitalization, no. (%)‡  10 (91)  25 (96)§  35 (97) 
Deaths, no. (%)¶  1 (9)  1 (4)  2 (5) 
*Ethnicity data missing from 4 cases; denominator = 27. 
†Vaccine history missing from 3 cases; denominator = 8. 
§Hospitalization data missing from 5 cases; denominator = 26. 
‡Vaccine history missing from 7 cases; denominator = 24. 
¶Death data missing from 5 cases; denominator = 26. 
Table 2. Cases and annualized incidence rate per 100,000 population of Invasive Haemophilus influenzae type a disease by age and 
ethnicity, 2000–2005* 
Demographic group  Total no. (range/y); rate (range/100,000/y) 
Alaska, no. cases 
(rate) 
Northern Canada, 
no. cases (rate)  p value* 
Overall 42 (4–9); 0.9 (0.5–1.2)  11 (0.3)  31 (3.9)  <0.001
<2 y of age  30 (1–8) ;19.7 (4.0–31.4)  7 (5.7)  23 (79.1)  <0.001
Indigenous 35 (4–8); 2.9 (2.0–4.0)  8 (1.1)  27 (5.9)  <0.001
<2 y of age, indigenous  29 (1–8); 52.6 (11.2–86.2)  7 (20.9)  22 (101.9)  <0.001
*p value for rate, Alaska vs. northern Canada. INTERNATIONAL POLAR YEAR  RESEARCH
sulfa resistance; 2 of the 10 (20%) demonstrated intermedi-
ate resistance.
PFGE and PCR analysis
PFGE was performed on 9 Hia isolates from Alaska 
and 19 isolates from northern Canada. With 1 exception, 
all isolates were found to be closely related (<3-band dif-
ference) with a Dice correlation of >85% (Figure 2). All 
28 isolates were negative for the IS1016-bexA deletion by 
PCR.
Discussion
Our data demonstrate that 69% of invasive H. inﬂ  uen-
zae disease in the North American Arctic is now caused by 
non-b serotypes (Alaska 51%; northern Canada 89%) with 
serotype a comprising almost half of cases (Alaska 24%; 
northern Canada 74%). Hia is now the most prevalent sero-
type in the North American Arctic. The clinical features of 
invasive Hia cases were similar to those of invasive disease 
caused by Hib. The overall annualized incidence of Hia in 
children <2 years of age living in the North American Arc-
tic was 19.7 cases per 100,000 children (Alaska 5.7; north-
ern Canada 79.1) in contrast to the rate of 0.83 cases of 
non–type b invasive H. inﬂ  uenzae disease among US chil-
dren <5 years of age (7). The overall annualized incidence 
rate among indigenous children <2 years of age residing 
in the North American Arctic was particularly high at 52.6 
cases per 100,000 children (Alaska 20.9; northern Canada 
101.9).
Widespread use of Hib conjugate vaccine has resulted 
in a dramatic decline in invasive Hib disease in the United 
States and Canada (7,8), including among indigenous chil-
dren in the North American Arctic (7,8,14) and the south-
western United States (12,27). However, the potential for 
serotype replacement remains a concern (16). Three popu-
lation-based studies have documented small increases in 
the incidence of non–type b H. inﬂ  uenzae disease after the 
introduction of the Hib conjugate vaccine (28–30). Several 
recent studies conducted in different countries have dem-
onstrated a predominance of serotype a disease. A study by 
Tsang et al. in Manitoba, Canada, found that most of the 52 
H. inﬂ  uenzae cases reported during 2000–2004 were caused 
by serotype a (50%) or nonserotypeable isolates (38.5%) 
(31). Ribeiro et al. noted an 8-fold increase in the incidence 
of Hia meningitis from the prevaccine (0.02 per 100,000 
population) to postvaccine period (0.16 per 100,000 popu-
lation) in Brazil (32). However, more recently published 
data by this group demonstrate that the increase in inci-
dence during the year following vaccine introduction was 
not observed in subsequent years (33). A study by Millar 
et al. has demonstrated high rates of invasive Hia disease 
among Navajo and White Mountain Apache children in the 
southwestern United States, although no increase in Hia 
incidence was noted after the introduction of Hib vaccine 
(10).
Clinical manifestations of invasive Hia disease were 
similar to those of invasive Hib disease in the prevaccine 
era (29). Meningitis was more common among Hia infec-
tions than in infections caused by encapsulated non-a and 
non-typeable Hi infections (37% vs. 24% and 12%, respec-
tively, p = 0.05); conversely, pneumonia was less common 
(32% Hia vs. 41% encapsulated non–a H. inﬂ  uenzae and 
40% nontypeable H. inﬂ  uenzae); however, this ﬁ  nding was 
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Table 3. Clinical illness in Alaskan and northern Canadian children and adults with invasive Haemophilus influenzae type a disease, 
2000–2005*
Alaska (n = 11)  Northern Canada (n = 31)  North American Arctic (n = 42) 
Diagnosis
Children (n = 7), 
no. (%) 
Adults (n = 4), 
no. (%) 
Children (n = 27), 
no. (%) 
Adults (n = 4), 
no. (%) 
Children (n = 34), 
no. (%) 
Adults (n = 8), 
no. (%) 
Meningitis 2 (29)  0 12 (44)  0 14 (41)  0
Pneumonia 3 (43)  3 (75)  4 (15) 2 (50)  7 (21)  5 (62) 
Bacteremia 0 1 (25)  6 (22) 1 (25)  6 (18)  2 (25) 
Septic arthritis  2 (29)  0 3 (11)  0 5 (15)  0
Other†  0 0 2 (8)  1 (25)  2 (3)  1 (13) 
*Children, <18 years of age; adults, >18 years of age. 
†Includes osteomyelitis (1 child), pericarditis (1 adult), and cellulitis (1 child). 
Figure 2. Pulsed-ﬁ   eld gel electrophoresis of representative 
Haemophilus inﬂ  uenzae serotype a isolates from Alaska and 
Northern Canada, 2000–2005 (N = 14). Haemophilus inﬂ  uenzae Serotype a, North American Arctic
not statistically signiﬁ  cant. Clinical disease varied with age 
when treatment was sought; meningitis was more common 
in children, and bacteremic pneumonia was more common 
in adults. The differing age distribution of Hia patients 
compared to patients with non-a and nontypeable infec-
tions may account for the differing clinical illnesses. In-
vasive Hia disease tended to occur among young children 
and nontypeable H. inﬂ  uenzae infections among adults 
(median age 1.1 vs. 39.2 years, respectively, p = 0.0003). 
The higher median age of patients infected with nontype-
able H. inﬂ  uenzae is consistent with results of a recent US 
study that demonstrated an increase in the number of cases 
of invasive nontypeable H. inﬂ  uenzae among adults (30) in 
the postvaccine era, and a study by McVernon et al. in Eng-
land and Wales that showed an increase in invasive non-b 
H. inﬂ  uenzae among older age groups (34).
There are several possible explanations for the high 
proportion of Hia among invasive H. inﬂ  uenzae disease in 
the surveillance population. First, an increase in virulence 
might explain the current predominance of serotype a. The 
IS1016-bexA deletion enables production of more capsule, 
which is thought to be the major virulence factor for inva-
sive disease (26,35). However, Hia isolates from Alaska or 
northern Canada tested negative for the bexA deletion, and it 
appears unlikely that the high rates of invasive Hia disease, 
particularly among indigenous children in this region, are 
due to introduction of a particularly virulent strain of Hia. 
If a new highly virulent Hia strain were introduced into the 
North American Arctic in the postvaccine period, subtyp-
ing data may show a clonally restricted pattern. We found a 
high degree of relatedness with a predominance of 1 clone 
across the North American Arctic. However, these data do 
not directly support the introduction of a virulent clone be-
cause other studies suggest limited genetic diversity of Hia 
(18,36). Second, widespread use of Hib conjugate vaccine 
and the subsequent reduction in Hib colonization may have 
opened an ecologic niche for increased colonization with 
Hia or other non-Hib strains. Little data regarding carriage 
of non–type b strains of H. inﬂ  uenzae are available; how-
ever, an investigation of a cluster of 5 of the invasive Hia 
cases in Alaska found that among 31 close contacts of case-
patients, 5 (16%) were colonized with Hia. Two of the 3 
case-patients were infants with recurrent Hia disease; reex-
posure is the likely explanation for disease recurrence (11). 
Finally, a preexisting background rate of non-b serotype 
disease may have simply been uncovered due to the de-
creasing Hib rates. Further studies of invasive H. inﬂ  uenzae 
disease are needed to describe clinical and epidemiologic 
features, characterize the pattern and rates of colonization, 
determine risk factors for carriage, and further characterize 
the strains by using molecular techniques.
Hia disease raises many questions from a public health 
response perspective. While chemoprophylactic regimens 
are well described for contacts of persons with Hib disease 
(37), the utility of chemoprophylaxis or other public health 
prevention measures for non-b typeable disease such as 
Hia is not clear. Further research is needed to provide clear 
guidance to practicing physicians caring for patients with 
Hia disease.
This study has several limitations. Alaskan and north-
ern Canadian data on non-b invasive H. inﬂ  uenzae disease 
were not collected in the pre-Hib conjugate vaccine era, 
making it difﬁ  cult to determine baseline or prevaccine in-
cidence of serotype a in this region. We did not collect de-
tailed clinical and demographic information beyond what 
was available from medical record review, and therefore 
we were not able to assess other factors (e.g., H. inﬂ  uen-
zae carriage among case-patients, within the community, 
or among close contacts). In addition, most H. inﬂ  uenzae 
isolates are serotyped by using slide agglutination only. Be-
cause PCR is not yet routinely used throughout the ICS net-
work for serotyping, nontypeable strains could have been 
misclassiﬁ  ed as encapsulated strains.
This article analyzed population-based surveillance for 
invasive H. inﬂ  uenzae disease across the North American 
Arctic. We identiﬁ  ed a high proportion of non-b serotypes 
over the 6-year study period, with particularly high rates 
of invasive disease caused by Hia. The reason for these 
high rates of invasive Hia disease is unknown and is likely 
multifactorial. While Hia incidence rates are high among 
particular groups in the North American Arctic, case num-
bers remain low (4–9 cases per year) and are lower than 
Hib rates in the prevaccine era. Hib vaccination remains 
one of the great public health success stories. Continued 
surveillance for H. inﬂ  uenzae disease is needed; however, 
to identify emerging problems and provide data necessary 
to develop effective prevention strategies.
The changing epidemiology of invasive H. inﬂ  uenzae-
disease highlights the importance of continued surveillance 
for invasive H. inﬂ  uenzae disease in regions of the world 
where Hib conjugate vaccine is currently in use. ICS will 
continue to monitor invasive disease caused by all H. in-
ﬂ  uenzae serotypes in the North American Arctic and other 
participating Arctic countries.
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